Areteia Therapeutics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Areteia Therapeutics (formerly TPI) is developing dexpramipexole, an oral eosinophil-depleting drug for eosinophilic asthma and EGPA; raised $215M in a Series B in 2023; Phase 3 EXHALE trial ongoing;
About
Areteia Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral treatments for eosinophil-driven diseases, particularly severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). The company was formerly known as TPI Therapeutics and rebranded as Areteia upon securing significant venture financing. Its lead compound, dexpramipexole, is a small molecule that selectively inhibits eosinophil maturation in the bone marrow — reducing circulating eosinophil levels by 75-90% without the immunosuppressive effects that can accompany broad anti-inflammatory drugs.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.